Is the Femtech Market growing now?

Why is the femtech growth answer so hard?

Because the femtech market is not giving one clean signal right now.

We found real momentum in menopause care, fertility benefits, wearables, AI diagnostics, and strategic funding. But we also found enough stress signals.

The positive case is actually strong. In late 2025, Business Insider reported that Midi Health raised a $50 million Series C and was serving about 20,000 women per week. In January 2026, Verdane announced a strategic investment in Clue after the period-tracking app crossed 100 million downloads. In May 2026, Oura launched global hormonal birth control and menopause features for its smart ring users. In June 2026, AP reported that Melinda French Gates pledged another $215 million to women’s health, including menopause and maternal mental health.

The negative case also exists. In October 2025, Business Insider reported that Tia cut 23% of its workforce after fundraising feedback pushed the company toward faster profitability. In 2025, Elvie was acquired by Willow after falling into administration, a brutal signal for premium femtech hardware economics. Flo, the largest period-tracking app, became the center of a major privacy case: Flo and Google agreed to pay $56 million, while Meta was found liable by a California jury in August 2025. In India, Times of India reported in mid-2025 that femtech funding fell from $70 million in 2021 to $8.7 million in 2024 and roughly $2 million in early 2025. And in Q3 2026, the FutureFemHealth tracker counted more deals than in Q2 but 40% fewer dollars.

That is the tension. Femtech is not dying. But the growth is not broad, easy, or evenly distributed.

Are femtech analysts still calling for growth?

Femtech analysts are still calling for growth. But, when we look at it, we can see that their numbers disagree, mostly because they define the market differently.

Fortune Business Insights estimates the femtech market at $9.12 billion in 2025, $10.67 billion in 2026, and $41.14 billion by 2034. Mordor Intelligence is similar in scale, estimating $8.56 billion in 2025, $9.78 billion in 2026, and $18.98 billion by 2031. Those forecasts treat femtech more narrowly, mostly around software, devices, diagnostics, and digital women’s health services.

Other firms use broader definitions. Grand View Research estimates femtech at $39.29 billion in 2024 and $97.25 billion by 2030. Global Market Insights estimates $66.2 billion in 2025 and $73.4 billion in 2026. The Business Research Company estimates $46.47 billion in 2025, $55.88 billion in 2026, and $118.99 billion by 2030. Those larger numbers usually include more healthcare services, products, devices, and adjacent women’s health categories. Narrow and broad femtech definitions explain gaps like these, which is why our femtech market report states what counts and what doesn't.

The consensus is not on size but on direction. Every credible forecast we found expects femtech or women’s health technology to grow in 2026. So, analysts see structural demand, but the huge spread in 2026 estimates, from roughly $10 billion to more than $70 billion, tells us the category is still fuzzy.

So analyst forecasts are useful, but only as one layer of evidence. The core of the answer needs ground-level signals.

Are femtech startups raising serious money right now?

Femtech funding is still alive, but investors are being selective.

We found enough recent rounds to say capital is flowing, especially into clinically anchored categories. September 2026 alone brought three sizable rounds: India’s Nua raised a reported $50 million Series C, Evvy raised a reported $40 million Series B for vaginal microbiome testing, and Teal Health announced a $22 million Series A for its FDA-authorized at-home cervical cancer screening.

The strongest signal is Midi Health. In late 2025, Business Insider reported that the company raised a $50 million Series C, reached about $150 million in total funding, and was running at a $150 million revenue rate. That is capital following a business that already has revenue, insurance coverage, and a clear use case.

Funding activity continued in 2026. Femtech Insider’s April 2026 investment round-up listed ONTO Health raising $20 million for AI-enabled fertility and longevity care and Osteoboost Health raising $8 million to scale its FDA-cleared wearable for postmenopausal bone health. Its March 2026 round-up included myStoria, Coral, and Prickly Pear Health, while January 2026 included Origin, Evaro, and Pinky Promise. New Market Pitch also tracked 107 femtech funding deals across 2024 to Q2 2026.

Money is not flowing evenly into anything labeled “femtech.” The fresh rounds cluster around menopause, fertility, diagnostics, bone health, brain health, and AI-enabled care. The totals also cooled: tracked Q3 2026 funding fell even as the number of deals rose, as detailed below.

That suggests the market is maturing away from generic wellness apps and toward higher-acuity problems where payers, employers, regulators, or clinicians can justify spend.

Are new femtech startups still being created?

New femtech startups are still entering the market, but they look more technical and clinical than before.

The new wave is less “period app with content” and more “diagnostic, wearable, AI workflow, or specialty care.”

IdentifyHer is a good example. In late 2025, the company opened U.S. pre-orders for Peri, a wearable for perimenopause symptom tracking, and the device formally launched in April 2026. Diamens raised funding in March 2026 to accelerate certification of a menstrual-blood-based endometriosis diagnostic. ONTO Health raised funding for AI-enabled fertility and longevity care. Prickly Pear Health expanded its pre-seed round for AI-powered women’s brain health.

Early rounds back this up: FutureFemHealth reported that more than half of the 45 women’s health deals it tracked in Q3 2026 were pre-seed or seed.

This founder pattern shows that femtech creation has not stopped. It has actually moved into harder, more defensible problems: endometriosis diagnosis, menopause measurement, fertility care, bone health, and women-specific AI.

The weak spot here is proof. Startup creation alone does not mean customers are buying. Many of these companies still need clinical validation, payer access, regulatory clearance, or employer distribution. But the entry pattern is healthier than another wave of thin consumer apps.

Are big companies finally taking women’s health seriously now?

Big companies are finally treating femtech as a real expansion lane, and this is one of the clearest current growth signals.

Oura is the best example. As mentioned above, in May 2026, it launched Hormonal Birth Control support and Menopause Insights globally for Gen3 and Ring 4 members. These features build on Cycle Insights, Fertile Window, Pregnancy Insights, and a women’s health AI model. The key is distribution: The Guardian reported in 2026 that Oura had sold 5.5 million rings globally, had around 5 million paying subscribers, and reached $1 billion in 2025 revenue. A women’s health feature inside that platform scales much faster than a standalone femtech app.

Hims & Hers is another signal. In late 2025, the company launched menopause and perimenopause care. Then, in May 2026, it reported Q1 revenue of about $608 million, nearly 2.6 million subscribers, and raised full-year 2026 revenue guidance to $2.8 billion to $3.0 billion. Hims & Hers is not a pure femtech company, but its move into menopause tells us that large consumer-health platforms now see women’s hormonal health as a revenue category. Who competes where, from specialist startups to broader consumer-health players, is shown on the market maps in our market report about femtech.

Eight Sleep also launched Hot Flash Mode in 2025, reporting that menopausal users experienced 55% fewer nighttime hot flashes on average in its cited data. That is a smaller signal, but it shows something important: femtech growth is now being embedded into mainstream sleep, wearable, and health platforms, not only sold by specialist women’s health brands.

Pharma and medtech buyers are moving too. In October 2026, Ferring agreed to acquire Gameto, and Hologic agreed to buy Barcelona-based Reveal Genomics, maker of the HER2DX breast cancer test. Incumbents are now bidding for women’s health assets, not just adding features.

Is menopause becoming femtech’s hottest growth market?

Menopause is the strongest current femtech growth segment.

It’s not just media hype: the evidence is unusually dense across funding, regulation, consumer products, clinical care, and prescription demand.

Midi Health is the anchor signal here. As seen above, Business Insider reported its $150 million revenue run rate and said it was serving around 20,000 women per week. Hims & Hers entered menopause care in late 2025. Oura launched Menopause Insights in May 2026, and its women’s health hub now covers perimenopause alongside cycle and pregnancy tracking. MyCelsius launched a cooling bracelet for hot flush management, and IdentifyHer launched a perimenopause wearable.

The regulatory backdrop also improved. In February 2026, the FDA approved labeling changes to six menopausal hormone therapy products, removing or clarifying some restrictive warning language. Verywell Health reported in April 2026 that estrogen patches were hard to find because demand surged after the policy change. That shortage is a rare real-world signal: women were not only reading about menopause care; they were filling prescriptions.

The gap is fresh revenue proof: we found no newer menopause-specialist revenue figure than Midi’s.

Are fertility benefits still a femtech growth engine?

Fertility and family benefits are still growing, but the market is more disciplined than explosive.

The clearest evidence comes from Progyny and employer-benefits platforms.

Progyny reported record Q2 2026 revenue of $350.5 million in August 2026, up 5.3% from $332.9 million a year earlier. Fertility benefits revenue rose 7.6% to $230.2 million, while pharmacy benefits revenue grew 1.2% to $120.3 million. The company now guides full-year revenue to $1.360 billion to $1.385 billion, a narrower range than its February guidance of roughly $1.355 billion to $1.405 billion. That is real, steady growth, but not acceleration.

Fertility also drew the period’s biggest strategic bet: Ferring’s proposed Gameto purchase, covered below.

Maven’s 2026 State of Women’s and Family Health Benefits report also shows that employers are still actively studying fertility, family health, virtual care, GLP-1 demand, access barriers, and AI trust. That does not prove every employer is increasing spend, but it does show that women’s and family health benefits remain a live budget topic in 2026.

The nuance is that fertility benefits are no longer an easy “up and to the right” story. Progyny’s pharmacy line is barely growing, and fertility treatment remains expensive. We see current growth, but it is tied to employer ROI, retention, utilization management, and benefit design, not unlimited demand.

Is the Flo privacy case breaking trust in femtech apps?

Not in usage numbers, at least not yet. Women are still using major femtech apps, but the app-only model is under more pressure.

We actually see huge usage, continued investment, and serious trust risk at the same time.

Clue announced a strategic investment from Verdane in January 2026 after crossing 100 million downloads. Flo remains the most visible period-tracking app; Business of Apps still describes it as the most popular women’s health app, with more than 60 million active users. Natural Cycles was estimated by Latka at about $63 million ARR in 2025, and it remains one of the few consumer women’s health apps with a regulated contraception position. Which women's health problems users will actually pay to solve, rather than just download an app for, is studied in our report covering the femtech market.

But privacy is now a growth constraint. In 2025, Google and Flo agreed to pay $56 million in a class-action settlement, and a California jury found Meta liable for illegally collecting sensitive Flo user data. An October 2026 notice put the proposed Flo-related settlements at $59.5 million in total; defendants deny wrongdoing, and we found no confirmed final court approval. That does not prove women are abandoning period apps, but it changes the economics of the category. Trust, compliance, consent flows, and data architecture are now part of the product.

Are wearables becoming the new femtech distribution channel?

Wearables are becoming one of the most important femtech distribution channels right now. The reason is obvious: they already sit on the body, collect longitudinal data, and have subscription models.

Oura is the clearest proof with its launch of hormonal birth control and menopause features globally. It had already moved into cycle tracking, fertility, pregnancy, and women’s health AI. The Guardian reported in 2026 that Oura had sold 5.5 million rings globally and had about 5 million paying subscribers. That gives femtech features instant distribution at a scale most women’s health startups cannot reach alone.

Partnerships reinforce the point. In 2025, Maven partnered with Oura to integrate ring biometric data into women’s health care. In 2026, Oura acquired Galen AI to strengthen clinical data integration and personalized health insights. These moves suggest women’s health is not just a content layer; it is becoming part of wearable-data infrastructure.

The limit is valuation, not usage. Axios reported that Oura postponed its IPO on September 29, 2026, so public markets have not yet priced that business.

Are femtech companies proving revenue, not just hype?

Some femtech companies are proving revenue growth, but many are not. This is one of the sharpest divides in the market right now.

Midi Health is the strongest private-company proof point. As we pointed out a couple of times in this analysis, Business Insider reported a $150 million revenue run rate in 2025, up from about $60 million at the end of 2024. Progyny remains the cleanest public benchmark, with record Q2 2026 revenue of $350.5 million, up 5.3% year on year. Hims & Hers is not pure femtech, but its Q1 2026 results show that a large consumer-health platform can add women’s health categories on top of a fast-growing subscription base.

The counterexamples matter. Tia’s October 2025 layoffs show that membership growth does not automatically create sustainable economics. Its CEO told employees the company needed a faster path to corporate-level profitability after fundraising feedback and underperformance. Elvie’s administration-led sale also shows that even admired femtech hardware brands can struggle with capital intensity, IP disputes, and scaling costs.

Many newer players report other metrics instead. Fortune reported in September 2026 that Evvy’s vaginal microbiome dataset had reached 100,000 patients, but no revenue figure came with it, and a large dataset is not the same as proven test accuracy for every condition.

So it looks like revenue growth exists, but it is not category-wide.

Why did femtech funding drop in Q3 2026 when deal count rose?

Because investors are writing more, but much smaller, checks. They are paying more attention to femtech, but they are not funding everything.

FutureFemHealth’s tracker shows the pattern. It counted 45 women’s health rounds worth $456.2 million in Q3 2026, against 40 rounds in Q2, but dollar funding fell 40%. The median round dropped from about $8 million to $3.1 million. That points to active early-stage investing and fewer large rounds. It is one tracker with its own definition.

PitchBook reported that femtech companies raised $1.2 billion in 2024 and surpassed $5 billion in total VC deal value since 2020. Silicon Valley Bank’s women’s health report coverage said investment reached a record $2.6 billion in 2024, nearly $1 billion above 2023, and that broader women’s-health-related investment reached $10.7 billion when including conditions that affect women differently or disproportionately.

The more recent signal is institutional infrastructure. In October 2025, the Women’s Health Fund launched a fund-of-funds model aiming to activate capital from managers with an anticipated $60 billion in AUM. In June 2026, AP reported that Melinda French Gates pledged another $215 million to women’s health globally, after more than $600 million over two years.

The problem is allocation. The World Economic Forum and Boston Consulting Group reported in January 2026 that women’s health still captures only 6% of private healthcare investment. That means interest is increasing from a very low base. Investors are paying attention, but the market remains underfunded relative to the size of the population and disease burden. Where investor money goes as attention to women's health grows, and what investors now avoid, is tracked in our report on femtech.

Is Ferring’s $1.38B Gameto deal a sign femtech exits are back?

Partly. It is one of the strongest strategic signals femtech has seen in 2026, but it is a signed proposal, not cash in hand. Femtech M&A still shows both strength and distress.

In October 2026, Ferring agreed to acquire Gameto for up to $1.3825 billion. The total depends on development, regulatory, and commercial milestones, the upfront amount was not disclosed, and the deal had not closed at last check. Gameto’s lead asset, Fertilo, is still in Phase 3. The same month, Hologic signed a definitive agreement to buy Reveal Genomics; closing depends on Spanish regulatory approval.

The strategic side is also visible in larger women’s health assets. Blackstone and TPG agreed to acquire Hologic for $18.3 billion, with the deal including a contingent value right tied to breast health revenue goals in fiscal 2026 and 2027. Hologic is not a startup, but the deal shows financial buyers still value women’s health infrastructure.

The distress side is just as clear. Elvie was acquired by Willow after falling into administration, and Financial Times coverage pointed to litigation and scaling difficulty. In India, Proactive For Her was acquired by IVF Access in May 2025, which looks less like a frothy exit and more like consolidation from digital women’s health into fertility clinic infrastructure.

The interpretation is nuanced. M&A is active, and headline values are rising, but a milestone ceiling is not an exit already paid. Buyers are not always paying premium prices for breakout growth. Some deals are about distribution, survival, IP cleanup, or integrating fragmented women’s health services into larger clinical platforms.

Are femtech rules helping growth or making it harder?

Regulation is helping femtech in menopause and diagnostics, but making sensitive-data apps more exposed. The net effect is mixed, and it is becoming more important.

The FDA’s February 2026 hormone therapy label changes are a direct tailwind for menopause care. By clarifying risk language for six menopausal hormone therapy products, the FDA reduced one of the psychological barriers to treatment. The estrogen patch shortage reported by Verywell Health in April 2026 suggests the regulatory change translated into real demand.

Public funding is also pushing regulated innovation. ARPA-H’s Sprint for Women’s Health committed roughly $110 million across 23 projects, including endometriosis diagnostics, brain health, reproductive health, and cardiovascular health. Even with setbacks, such as Aspira’s ARPA-H contract termination in June 2025, the signal is more evidence-driven, milestone-based funding.

FDA authorization is also becoming a funding argument. Teal Health raised its $22 million Series A in September 2026 on the back of its FDA-authorized self-collected HPV test. It expects broad U.S. insurance coverage in January 2027; that is a stated goal, not coverage in place.

The downside is privacy regulation and litigation. Flo’s case, now tied to $59.5 million in proposed settlements, shows that reproductive health data is a legal and reputational risk.

For femtech apps, regulation is not just a compliance cost; it can become a growth constraint if users stop trusting how intimate data is handled.

Are femtech diagnostics finally moving beyond awareness?

Femtech diagnostics are finally showing real movement, especially in endometriosis. The products are still early, but the recent signals are more concrete than usual.

The strongest recent science signal is endometriosis imaging. In April 2026, researchers reported promising trial results for a non-invasive scan using the radiotracer maraciclatide. In a 19-woman trial, results matched surgical findings in 16 cases without false positives. The sample is small, but the signal matters because endometriosis diagnosis can still take years and often involves invasive procedures. Which femtech technologies already work, and which are still in early trials, is sorted out in our femtech market report.

Commercial diagnostics are also moving, and money followed in September 2026. Evvy raised a reported $40 million for clinically interpreted vaginal microbiome testing, and Teal Health raised $22 million for at-home cervical cancer screening. Diamens raised funding in March 2026 to accelerate certification of a menstrual-blood-based endometriosis diagnostic. Aspira said in April 2026 that it planned to finish a molecular laboratory buildout in Q2 2026 for ENDOinform, despite losing its ARPA-H contract in 2025.

So, femtech diagnostics are now moving from “we need awareness” to “we need validated tests.” That is a healthier growth signal. It means the category is trying to solve measurable bottlenecks, not only educate consumers. Test accuracy, patient outcomes, and insurance payment are still separate hurdles.

Are women spending less on femtech products?

We do not see strong evidence that women are broadly spending less on femtech products. The pressure is clearer in company economics than in end-user demand.

The best demand-side counterexample is menopause. After the FDA’s February 2026 hormone therapy label changes, Verywell Health reported estrogen patch shortages in April 2026 because demand increased. That is a direct signal that some women are spending more on menopause care, not less.

Wearables also point against a broad spending pullback. Oura’s women’s health features are being added to a large paid subscription base, and The Guardian reported around 5 million paying subscribers in 2026. That does not isolate women-only spend, but consumers are still paying.

Fertility spending is holding up too: Progyny’s fertility benefits revenue rose 7.6% in Q2 2026. That is employer money, not household spending, and we found no consumer spending index for women’s health covering mid-2026.

The weak point is clinic economics. Tia’s layoffs show that a company can have consumer demand and still struggle if the care model is too expensive to operate.

So we would not say femtech customers are pulling back. They spend when the product is accessible, trusted, clinically useful, and priced against a clear pain point.

Are femtech layoffs and failures getting worse?

Femtech layoffs and failures are visible, and the category is now going through a quality filter.

Tia’s 23% workforce cut is the clearest recent layoff signal. It affected corporate staff, providers, and field support, and management tied the move to profitability pressure and fundraising feedback. That is a direct warning for hybrid women’s health clinic models.

Elvie is the clearest failure-like signal. A major UK femtech brand, backed by prominent investors and known for breast pumps and pelvic health devices, fell into administration before Willow acquired the business and assets. The brand continues, but the corporate outcome is not a clean growth story.

India adds another warning. Times of India reported in mid-2025 that femtech funding had fallen sharply after 2021 and that consolidation was rising. That suggests some regions may not support a large number of standalone femtech startups right now.

The Q3 2026 drop in median round size to $3.1 million could squeeze mature companies that need larger checks. We found no reliable count of femtech closures for the period, so one weak quarter does not prove failures are rising.

Taken together, these cases show that weak unit economics, expensive hardware, clinic operations, and unclear distribution are being punished.

Is femtech demand growing outside the U.S.?

Femtech demand is growing outside the U.S., but the market is uneven. We see activity in Europe, global philanthropy, India, cross-border M&A, and wearables, but funding depth differs sharply by region.

Europe is active. Verdane’s January 2026 investment in Clue is a major European consumer femtech signal. Oura, a Finnish-American company, is rolling out women’s hormonal health features globally. Diamens, based in Austria, is working on menstrual-blood-based endometriosis diagnostics. MyCelsius launched in the UK with a menopause cooling bracelet. Launches and rollouts outside the U.S. are among the market signals we follow every quarter in our market report about femtech.

Global philanthropy is also expanding. In June 2026, AP reported that Melinda French Gates pledged $215 million to women’s health, including maternal mental health in Africa and menopause care in the U.S. That matters because femtech and women’s health funding are not only moving through U.S. venture capital.

Cross-border deals add to this: Swiss-based Ferring has agreed to buy U.S.-based Gameto, and Hologic has agreed to buy Spain’s Reveal Genomics.

India shows the unevenness. Times of India reported that Indian femtech funding fell from $70 million in 2021 to $8.7 million in 2024 and roughly $2 million in early 2025. In September 2026, though, Nua raised a reported $50 million Series C. One round does not reverse the trend.

Is femtech media hype turning into real demand?

Femtech media hype is turning into real demand in menopause, but not everywhere. The clearest conversion happens when attention meets a reimbursable, purchasable, or clinically useful solution.

Menopause is the proof. The FDA label change, Hims & Hers’ menopause launch, Midi’s revenue growth, Oura’s Menopause Insights, IdentifyHer’s perimenopause wearable, and estrogen patch shortages all point in the same direction. This is not just awareness. It is product launches, care delivery, subscriptions, and prescription demand.

But hype can also create low-quality growth. The Guardian warned in February 2026 about a “menopause gold rush,” with experts concerned that unregulated brands may exploit symptoms with weak evidence. That matters because femtech’s biggest opportunity is also its biggest risk: women have been underserved for so long that the market can attract both serious care models and opportunistic wellness products.

Outside menopause, Progyny’s revenue and Teal’s FDA-authorized test are also real demand, not headlines.

The best growth is happening where awareness is paired with evidence, clinical access, and user trust. The weakest growth is where companies sell anxiety without proof.

Is femtech growing right now?

Femtech is growing right now, but unevenly. The current evidence points to selective expansion, not a broad, frictionless boom.

We would not call this an easy market. Tia’s layoffs, Elvie’s administration-led sale, India’s funding dip, Flo’s privacy litigation, the 40% drop in tracked Q3 2026 funding, and continued underinvestment relative to healthcare overall all matter. They show that femtech is not immune to profitability pressure, hardware scaling problems, data-trust issues, or regional capital shortages.

But the positive signals are stronger and fresher. In the last 9 to 12 months, menopause care has moved fast across startups, public companies, wearables, regulation, and prescription demand. Midi’s revenue run rate, Oura’s product expansion, Hims & Hers’ menopause launch, Progyny’s record Q2 2026 revenue, Clue’s strategic investment, and new diagnostics rounds such as Evvy and Teal all point toward expansion. Ferring’s Gameto deal and Hologic’s Reveal deal show buyers want women’s health assets, though neither has closed. Analyst forecasts also align on direction, even if their market-size definitions vary widely.

So the answer is yes, with a major qualifier. Femtech is currently growing, but the winners are not generic femtech brands.

The winners are companies solving high-pain, clinically credible, reimbursable, employer-relevant, or data-rich problems. The market is expanding while weaker business models are being filtered out.

Question	Verdict	Comment
Are analysts still bullish on femtech?	Yes	Forecasts differ widely, but major firms all project 2026 growth.
Are femtech startups raising serious money?	Yes	Nua, Evvy, and Teal raised $22M to $50M in September 2026, but Q3 totals fell.
Are new femtech startups still entering?	Yes	Over half of tracked Q3 2026 deals were pre-seed or seed; focus is clinical.
Are big companies taking women’s health seriously?	Yes	Oura and Hims & Hers added care lines; Ferring and Hologic signed acquisitions.
Is menopause femtech’s hottest segment?	Yes	Funding, FDA changes, product launches, and prescription shortages all point to demand.
Are fertility benefits still growing?	Mixed	Progyny grew Q2 2026 revenue 5.3%; growth is steady, not explosive.
Is the Flo case breaking trust in apps?	Mixed	Usage remains large, but $59.5M in proposed Flo settlements raises trust risk.
Are wearables becoming femtech channels?	Yes	Oura gives women’s health features instant distribution; its IPO was postponed.
Are femtech companies proving revenue?	Mixed	Midi, Progyny, and Hims show revenue signals; Tia and Elvie show pressure.
Why did Q3 2026 funding drop?	Mixed	More deals, but 40% fewer dollars and a $3.1M median round.
Is the Gameto deal a sign exits are back?	Mixed	Strong buyer interest, but the Gameto and Reveal deals are signed, not closed.
Are femtech rules helping growth?	Mixed	FDA changes and authorizations help; privacy litigation raises app risk.
Are femtech diagnostics accelerating?	Yes	Evvy and Teal rounds, Hologic’s Reveal deal, and endometriosis tests are advancing.
Are women spending less on femtech?	Not enough evidence	We see business-model pressure, but not clear broad demand decline.
Are femtech failures getting worse?	Mixed	Layoffs and failures exist, but they look like a market filter.
Is femtech demand growing outside the U.S.?	Mixed	Europe and cross-border M&A look active; India is weak but Nua raised $50M.
Is femtech hype becoming real demand?	Mixed	Menopause attention is converting into care and prescriptions, but hype risk remains.